Virus Mediated Diseases

There remains a strong demand for safe and effective therapies to treat viral infections. The company is committed to developing and commercializing antiviral products for treating and even preventing viral infections in humans and animals, both domesticated and commercial livestock.  Nerium oleander-based therapy represents a new safe approach to prevention as well as treatment of virus mediated disease in humans and animals.

Our products and a key ingredient, oleandrin, have now been shown to act in both a prophylactic as well as therapeutic manner against a wide variety of enveloped viruses. Data demonstrate that our products are effective at inhibiting viral replication within infected cells and at damaging viral progeny. The virus particles that are produced are ‘damaged’ and far less infective making them targets for our own human immune system.

We and our investors strongly believe in the potential benefits that our products might offer toward meeting the global needs. We strongly believe in the immediate socioeconomic impact our products can have in fighting virus mediated diseases and are aggressively pursuing their regulatory approval and commercialization for antiviral therapies in humans and animals.

Further Information: See “Product Development” or “Contacts”.

Human Antiviral Therapies

We have obtained data demonstrating significant activity of our products against extremely harmful viruses, such as SARS-CoV-2, cytomegalovirus, HSV-1, HIV, HTLV-1, Ebola virus, and other viruses.  According to the CDC, in the United States alone in 2020, viral infections accounted for two of the top ten leading causes of death in humans: SARS-CoV-2 having a death rate of 85 per 100K, and influenza/pneumonia with a death rate of 12.3 and 13 per 100K. The WHO reported the following statistics for 2020: HIV- fatalities of 680K and new infections of 1.5MM; HSV-1 infections of 3.7BB; HSV-2 infections of 491BB; HTLV-1 10MM or more; influenza severe infections of 3MM-5MM and 300K-650K fatalities. As of June 2022, COVID-19 accounts for almost 88MM cases and over 1MM deaths in the U.S. and almost 550MM cases and over 6MM deaths worldwide.

Animal Antiviral Therapies

Our products also exhibit significant antiviral activity against viruses of importance in commercial animals including cattle, pigs and horses. The data demonstrate the therapeutic and prophylactic antiviral activity of our products against bovine viral diarrhea virus (BVDV), bovine respiratory syncytial virus (BRSV), bovine coronavirus (BCV), porcine influenza virus (PIV), porcine reproductive and respiratory syndrome virus (PRRSV), porcine coronavirus (PCV), and equine encephalitis virus (EEV). In addition, we will explore antiviral activity against the most common and commercially important virus infections in poultry, sheep, dogs, and cats.